Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Patent: 6,881,407

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,881,407
Title: Method for treating hepatitis
Abstract:Hepatitis can be treated by administering to a patient in need thereof an effective amount of a compound that neutralizes the effects of secreted TNFalpha. Two types of these compounds are extracellular ligand binding proteins of the human p75 TNF receptor, such as etanercept (Enbrel), and humanized monoclonal antibodies that neutralize the activity of TNFalpha, such as inflixamab (Remicade).
Inventor(s): Amin; Ashok (Union, NJ), Abramson; Steven (Rye, NY)
Application Number:09/925,970
Patent Claims:see list of patent claims

Details for Patent 6,881,407

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Janssen Biotech, Inc. REMICADE infliximab For Injection 103772 1998-08-24 ⤷  Try it Free 2020-08-11
Immunex Corporation ENBREL etanercept For Injection 103795 1998-11-02 ⤷  Try it Free 2020-08-11
Immunex Corporation ENBREL etanercept For Injection 103795 1999-05-27 ⤷  Try it Free 2020-08-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.